Navigation Links
Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
Date:3/18/2008

BRISBANE, Calif., March 18 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) issued the following statement regarding today's indictment of a former employee in connection with the promotional activities for Actimmune(R) (interferon gamma-1b) during a period that ended in June of 2003.

"Today's indictment concerns conduct by a former employee who left the company more than four years ago.

"In 2006, InterMune settled all government claims related to that conduct, without criminal sanctions against the company. At the time, the government acknowledged that InterMune fully cooperated with its investigation and had instituted numerous and comprehensive compliance changes before the investigation even began. Today's government action does not affect the Company's settlement in any way.

"In today's action, the government is bringing charges against a former employee, not against InterMune, its current employees or its Directors.

"Since 2004, InterMune has been a transformed company with a new management team, a rigorous compliance program and a promising pipeline focused on serious pulmonary and hepatic diseases.

"We have taken great strides to put this matter behind us and have focused our resources on what we believe is a promising future for our Company and our shareholders."

The individual charged today was Scott Harkonen, formerly President, Chief Executive Officer and a Director of InterMune.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (H
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
2. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
3. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
4. APIC Statement on Need for Increased Prevention Measures for Healthcare-Associated Infections (HAIs)
5. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
6. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
7. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
8. Statement by John Bailey, Chief Scientist: The Personal Care Products Council Response to Study on Phthalate Exposure in Baby Care Products
9. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
10. Smithfield Foods, Inc. Statement Regarding Animal Cloning
11. Statement on the Release of the European Food Safety Assessment on the Safety of Food Derived From Clones and Their Offspring in the Food Supply
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2008)...Symbol: MS, EDMONTON, Oct. 3 /PRNewswire-FirstCal...loper in the treatment of multiple sclerosis (MS),...Monitoring Board (DSMB) for the,Company,s U.S. piv...8298),in patients with secondary progressive MS ha... the trial continue as per the protocol., This wa...
(Date:10/3/2008)...or Ap3ana, CTI,s ,personalized medicine, venture, ...erapeutics, Inc. (CTI),(Nasdaq: CTIC ) announced ...t recently President and COO of a Tyr Pharma and f...mics Institute of the Novartis Research,Foundation... Bresso, Italy,CTI Europe currently conducts the ...
(Date:10/2/2008)...2 /- Helix BioPharma,Corp. ... its private,placement announced on September 30, ...ss proceeds totaling CDN$11,424,000., Each unit c...mmon share,purchase warrant, with each whole commo...urchase, subject to adjustment, one common share a...
(Date:10/2/2008)...Provides Business Update to Investors, WILMINGTON...today at an,investor conference, DuPont Vice Presi...ny,s plans to bring its two advanced biofuels prog... technical progress toward the,commercialization o...stocks,economically into biofuels., "Biobutanol a...
Breaking Biology Technology:BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 3Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 4Helix Biopharma Closes $11.4 Million Private Placement 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 3
... Businesses could lose important trademark right...ents of the U.S. Patent and Trademark Office and t...ed by an international case of earlier this year. ...smetische Erzeugnisse mbH , the Trademark Trial an...nsion of time to oppose an international, or Madri...
... As Im writing this column, I was reminded by an...John Lennons birthday. , ,As he was born on Oct. 9...still alive. He was shot outside his apartment bui...ticle gave a fascinating perspective on probably t...this statement is going to provoke some comment bu...
... Madison , Wis. - Three UW-Madison scientists...m cells to turn into pancreatic islet cells, the ...nced last week. The procedure has the potential to...ble for transplantation into diabetic patients. , ...ahan, and Nathan R. Treff, have applied for a pate...
... At DEMO 2004 I hosted a panel The Rise of the B...om, blogging was pass; of course everyone was blog... blogging with a blank stare; what, after all, was...singly apparent as blogging moves from the journal...nal of corporate America. But 18 months since that...
Other Biology Technology:Ruling enforces international trademark electronic filing requirements 2Ruling enforces international trademark electronic filing requirements 3Midwest biotech stocks drop like a rock during the third quarter 2Midwest biotech stocks drop like a rock during the third quarter 3Blogging moves to corporate America 2Blogging moves to corporate America 3
(Date:10/5/2008)...n the Journal of Cell Biology how the altered be... in tumor cells., On 2D surfaces, cells may migra...ins, which link the cell to the extracellular matr...but exactly how has been unclear. Recent work has ...om movement, while an integrin called avb3 has bee...
(Date:10/5/2008)...8 Scientists report online this week in Nature ...t immune cells to a gene associated with Crohn,s d...valent inflammatory bowel disorder. , The link t... University School of Medicine in St. Louis becaus...d by misdirected immune responses in the intestine...
(Date:10/3/2008)...(Oct. 2, 2008)Researchers from Harvard Medical Sch...iscovered how beetles and bacteria form a symbioti...results in the destruction of pine forests. In add...at drives this whole phenomenon. , The context ...y arc that includes some of the most unlikely char...
(Date:10/3/2008)...life cycle of Atlantic bluefin tuna shows, for the... bluefin mix substantially as juveniles, but retur...arch findings have critical implications for how b...tic. , Research appearing in the journal Scien...of Texas A&M University and Dr. David Secor of the...
Breaking Biology News(10 mins):Form of Crohn's disease traced to disabled gut cells 2Cross kingdom conflicts on a beetle's back 2Cross kingdom conflicts on a beetle's back 3Scientists Find new migratory patterns for Mediterranean and Western Atlantic bluefin tuna 2Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2007 Results 3B Teleconference and Webcast to be held on September 18 2007 582 1Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2007 Results 3B Teleconference and Webcast to be held on September 18 2007 582 2Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2007 Results 3B Teleconference and Webcast to be held on September 18 2007 582 3Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2007 Results 3B Teleconference and Webcast to be held on September 18 2007 582 4Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2007 Results 3B Teleconference and Webcast to be held on September 18 2007 582 5Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2007 Results 3B Teleconference and Webcast to be held on September 18 2007 582 6Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2007 Results 3B Teleconference and Webcast to be held on September 18 2007 582 7Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2007 Results 3B Teleconference and Webcast to be held on September 18 2007 582 8Updated GOLD report presents new understandings in diagnosis treatment and prevention of COPD 1252 1Updated GOLD report presents new understandings in diagnosis treatment and prevention of COPD 1252 2USA TODAY Concludes Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration 1249 1USA TODAY Concludes Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration 1249 2USA TODAY Concludes Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration 1249 3Researchers discover correlation between GERD and obesity in females 1245 1
...at the University of California, San Diego has sho...e to sequence DNA as it passes through tiny pores....dicine closer to reality. , The paper, published i...cribes a method to sequence a human genome in a ma...ing the electrical perturbations generated by a si...
...have determined that night blindness is a new clin...rd Hughes Medical Institute (HHMI) international r...aveto of the Institute for Genetic Engineering and...ncil, National Council of Scientific Research and ...system of individuals with the tropical disease ca...
...d a method to engineer blood vessels within the ti...s have resulted in significant improvement in hear... Artificial Organs. , With heart disorders affec...easing mortality rates, there has been a need to d... challenges in the field of tissue engineering is ...
...resurrecting ancient genes, scientists have for th... of an apparently "irreducibly complex" molecular ...sistant professor of biology at the University of ...gy, and will be published in the April 7 issue of ...olution of complex molecular systems ?those in whi...
Other Biology News:Nanopore method could revolutionize genome sequencing 2Nanopore method could revolutionize genome sequencing 3A case of mistaken molecular identity 2A case of mistaken molecular identity 3Evolution of 'irreducible complexity' explained 2
Tissue-Stat ( Tissue Adherent for Mounting Formalin-Fixed and Frozen Tissue Sections.)
AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections.
...formulated for covering tissue sections and cell p...omogens producing alcohol soluble OR alcohol insol...ith chromogens such as Fast Red or AEC that requir..., such as DAB. No heating is required prior to use...
Rabbit polyclonal to JAK2 (phospho Y1007) ( Abpromise for all tested applications). Antigen: Synthesized phosphopeptide derived from human JAK2 around the phosphorylation site of tyrosine 1007 (
Biology Products: